Compare · EW vs HSCS
EW vs HSCS
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and HeartSciences Inc. (HSCS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and HSCS operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $50.78B, about 3296.7x HSCS ($15.4M).
- HSCS has been more active in the news (15 items in the past 4 weeks vs 5 for EW).
- EW has more recent analyst coverage (25 ratings vs 0 for HSCS).
- Company
- Edwards Lifesciences Corporation
- HeartSciences Inc.
- Price
- -
- -
- Market cap
- $50.78B
- $15.4M
- 1M return
- -
- -37.37%
- 1Y return
- -
- -14.53%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 5
- 15
- Recent ratings
- 25
- 0
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest EW
- SEC Form 4 filed by Edwards Lifesciences Corporation
- Barclays initiated coverage on Edwards Lifesciences with a new price target
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCT
- Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision
Latest HSCS
- SEC Form DEFA14A filed by HeartSciences Inc.
- SEC Form 424B5 filed by HeartSciences Inc.
- SEC Form DEFA14A filed by HeartSciences Inc.
- SEC Form 8-K filed by HeartSciences Inc.
- HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device
- SEC Form DEFA14A filed by HeartSciences Inc.
- Fortitude Secures Priority Supply Allocation for BITMAIN’s Next-Generation Zcash Mining Equipment, Announces $100 Million Non-Binding Purchase Commitment, and Additional Upsizing of DCG Credit Facility and Available ZEC Funding from DCG
- SEC Form DEFA14A filed by HeartSciences Inc.
- HeartSciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form DEFA14A filed by HeartSciences Inc.